Department of Onco-Cardiology, Osaka International Cancer Institute, Japan.
Department of Cancer Chemotherapy Center for Outpatients, Osaka International Cancer Institute, Japan.
Intern Med. 2021 Sep 15;60(18):2973-2977. doi: 10.2169/internalmedicine.5347-20. Epub 2021 Apr 5.
Pazopanib, a multi-targeted tyrosine kinase inhibitor, is associated with cardiovascular adverse events, such as hypertension, cardiac dysfunction, and thromboembolism. However, symptomatic pazopanib-related bradycardia is uncommon. We herein report a case of symptomatic bradycardia of 35 beats per minute in a patient with solitary fibrous tumor/hemangiopericytoma (SFT/HPC) treated with pazopanib for 1 month. His heart rate recovered to a normal range soon after pazopanib cessation. He restarted pazopanib at a reduced dose, which was continued without SFT/HPC progression or bradycardia recurrence. This case highlights the possibility of bradycardia induced by pazopanib and the importance of monitoring the patient's heart rate.
帕唑帕尼是一种多靶点酪氨酸激酶抑制剂，与心血管不良事件相关，如高血压、心功能障碍和血栓栓塞。然而，有症状的帕唑帕尼相关心动过缓并不常见。本文报告了 1 例接受帕唑帕尼治疗 1 个月的孤立性纤维瘤/血管外皮细胞瘤（SFT/HPC）患者出现 35 次/分钟有症状心动过缓的病例。在停止使用帕唑帕尼后，他的心率很快恢复到正常范围。他以较低剂量重新开始使用帕唑帕尼，并且没有出现 SFT/HPC 进展或心动过缓复发。本病例强调了帕唑帕尼引起心动过缓的可能性以及监测患者心率的重要性。
